Syncope, a transient loss of consciousness due to inadequate cerebral blood flow, presents a diagnostic challenge for healthcare professionals. It's a symptom, not a disease, and its underlying causes can range from benign to life-threatening.
Syncope accounts for 1-3% of hospital admissions and emergency department visits. It's crucial to differentiate syncope from other conditions that cause transient loss of consciousness, such as seizures. The key feature of syncope is its rapid onset, short duration, and spontaneous complete recovery.
Diagnosis requires a comprehensive approach, beginning with a detailed history and physical examination. The history should focus on the onset, duration, associated symptoms, and any precipitating factors. The physical examination should include orthostatic blood pressure measurements and a cardiovascular examination.
Further investigations depend on the initial assessment. Routine tests include electrocardiography and blood tests to exclude anemia or metabolic abnormalities. More specific tests, such as echocardiography or tilt-table testing, may be indicated based on clinical suspicion.
Management of syncope depends on the underlying cause. It can range from reassurance and lifestyle modifications for benign conditions to pharmacological treatment or even cardiac pacing for more serious disorders. Patient education about the nature of the condition and the importance of avoiding triggering factors is crucial.
Syncope is a common clinical problem that requires a systematic and comprehensive approach for diagnosis and management. By understanding the various causes and implementing a thorough evaluation process, healthcare professionals can effectively manage patients with syncope, improving their quality of life and potentially preventing serious complications.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation